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Background. To our knowledge, no study to date has compared the effects of a subunit influenza vaccine with
those of a virosomal influenza vaccine on immunocompromised patients.
Methods. A prospective, double-blind, randomized study was conducted to compare the immunogenicity and
reactogenicity of subunit and virosomal influenza vaccines for adult patients who had an immunosuppressive
disease or who were immunocompromised as a result of treatment.
Results. There were 304 patients enrolled in our study: 131 with human immunodeficiency virus (HIV)
infection, 47 with a chronic rheumatologic disease, 74 who underwent a renal transplant, 47 who received long-
term hemodialysis, and 5 who had some other nephrologic disease. There were 151 patients who received the
subunit vaccine and 153 patients who received the virosomal vaccine. A slightly higher percentage of patients from
the subunit vaccine group were protected against all 3 influenza vaccine strains after being vaccinated, compared
with patients from the virosomal vaccine group (41% vs. 30% of patients; ). Among HIV-infected patients,Pp .03
the level of HIV RNA, but not the CD4 cell count, was an independent predictor of vaccine response. Among
renal transplant patients, treatment with mycophenolate significantly reduced the immune response to vaccination.
The 2 vaccines were comparable with regard to the frequency and severity of local and systemic reactions within
7 days after vaccination. Disease-specific scores for the activity of rheumatologic diseases did not indicate flare-
ups 4–6 weeks after vaccination.
Conclusions. For immunosuppressed patients, the subunit vaccine was slightly more immunogenic than the
virosomal vaccine. The 2 vaccines were comparable with regard to reactogenicity. Vaccine response decreased with
increasing degree of immune suppression. Among HIV-infected patients, the viral load, rather than the CD4 cell
count, predicted the protective immune response to the vaccine.
Clinical trials registration. NCT00783380.
Influenza virus is responsible for annual epidemics as-
sociated with substantial morbidity and excess mor-
tality, particular among elderly persons, persons with
end-organ disease, and immunocompromised persons.
Prevention of influenza is usually achieved by the use
of vaccination programs. The efficacy of influenza vac-
cination depends on the antigenic shift and drift of the
virus and on the ability of a person’s immune system
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to adequately respond to the vaccine antigens. Unfor-
tunately, immunocompromised persons are not only at
a higher risk of morbidity and mortality due to influ-
enza infection but also show lower immune response
rates to vaccination [1–4]. The aim of the development
of new vaccine formulations has been to increase im-
munogenicity in patients while maintaining an accept-
able number of adverse effects in patients. Since their
introduction in 1943, several generations of influenza
vaccines have become available. Whole-cell influenza
vaccines have been replaced by split and subunit vac-
cines, which result in a lower number of adverse effects
in patients because the viral components of these vac-
cines, other than the vaccine antigen hemagglutinin
(HA), are excluded or because the number of viral com-
ponents is reduced. In virosomal vaccines, the antigens
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bind to phosphatidylcholine membranes with the aim of im-
itating the natural routes of infection and thereby increasing
immunogenicity in patients.
Trials that have compared virosomal influenza vaccines with
conventional vaccine formulations are scarce and have yielded
conflicting results. Two studies found higher seroconversion
rates and higher protective anti-HA antibody titers after vi-
rosomal vaccination than after whole-cell or subunit vaccina-
tion among residents of nursing homes and elderly people [5,
6]. These results could not be reproduced in another study of
a comparable patient population that compared a virosomal
vaccine with subunit and split vaccines [7]. One of these 2
studies investigated the adverse effects of these vaccines and
could not find a clear advantage of virosomal vaccines over
their comparators [5, 7].
No study has compared the immunogenicity and reactogen-
icity of virosomal vaccines with those of other vaccine for-
mulations in human immunodeficiency virus (HIV)–infected
patients. One trial evaluated a virosomal vaccine for both adults
and former intravenous drug users and found significantly
lower response rates among HIV-infected persons, irrespective
of CD4 cell count, than among HIV-uninfected participants
[8]. Similarly, in another trial [9], a virosomal vaccine had a
lower rate of immunogenicity among HIV-infected children
(even after suppression of HIV viremia) than among healthy
control subjects.
We conducted a randomized, double-blind, comparative trial
of subunit and virosomal vaccines for 304 patients with im-
munosuppression due to a variety of underlying diseases and
treatments. We assessed the immunogenicity and safety of these
vaccines, including the eventual reactivation of underlying con-
ditions such as HIV infection and chronic rheumatologic dis-
ease. To our knowledge, such a study has not been conducted
before.
METHODS
Our study was performed during the period from 17 October
through 16 December 2005 at the University Hospital Bern in
Bern, Switzerland. The study protocol was approved by the
local ethical review board and registered with ClinicalTrials.gov
(identifier NCT00783380).
Subjects. We enrolled immunosuppressed adults (16 years
of age) who were observed in the outpatient clinics of the de-
partments of rheumatology, nephrology, and infectious diseases.
Immunosuppression was attributable to either long-term he-
modialyis, long-term peritoneal dialysis, renal transplantation, or
treatment for HIV infection or rheumatologic disease. These
patient groups fulfilled the national recommendations for yearly
influenza vaccination (from the Federal Office of Public Health
in Switzerland; available at: http://www.bag.admin.ch). Excluded
from the study were inpatients, patients with an acute febrile
illness at the time of vaccination, and patients who, in the past,
had an allergic reaction to an influenza vaccine or to proteins
derived from chicken. All patients gave written informed consent
before enrollment.
Vaccines. The subunit vaccine (Influvac; Solvay Pharma
AG) and the virosomal vaccine (Influvac plus; Solvay Pharma
AG) were commercially available for use during the 2005–2006
influenza season. Both vaccines contained 15 mg of A/Califor-
nia/20/99 (H3N2)–like HA, 15 mg of A/New Caledonia/20/99
(H1N1)–like HA, and 15 mg of B/Shanghai/361/2002-like HA.
Patients were block randomized from each outpatient clinic.
At baseline, a serum sample was obtained for determination
of anti-HA antibody titers before vaccination. Patients with
rheumatologic disease had disease-specific scores that were
based on the Disease Activity Score for rheumatoid arthritis
[10], the Bath Ankylosing Spondylitis Disease Activity Index
for ankylosing spondylitis [11], the European Consensus Lupus
Activity Measurement for lupus erythematodes [12], and the
Disease Extend Index for Wegener granulomatosis [13].
The vaccine was administered by deep intramuscular injec-
tion into the deltoid muscle. For patients with a contraindi-
cation for intramuscular injection, the vaccine was adminis-
tered subcutaneously. The depth of the injection and the
immediate reaction of the patient were recorded. Patients re-
ceived a questionnaire for documentation of local and systemic
adverse effects during the first 7 days after vaccination. After
4–6 weeks, a second serum sample was obtained, and patients
with rheumatologic disease were examined for disease activity.
Serologic testing. Baseline and follow-up serum samples
were stored at 20C until further analyses. Anti-HA antibody
titers were determined by the World Health Organization Col-
laborating Centre for Reference and Research on Influenza at
the Universite´ Claude Bernard (Lyon, France). The antigens
used were the H3N2 A Panama strain for A California, the
H1N1 A New Caledonia for the A Caledonia, and the B Hong
Kong 330/2001 for the B Shanghai strain. The anti-HA antibody
titers were determined using the method described by Palmer
et al. [14]. Immunogenicity was defined as the attainment of
a protective anti-HA antibody titer of 40 or a seroconversion
rate of 1:4 for all vaccine strains at follow-up and in comparison
with baseline values.
Statistical analysis. All analyses were performed in Stata,
version 9 (StataCorp), using a cutoff of for 2-tailedP ! .05
tests. Differences between mean values were tested by use of
the Student’s t test or the Mann-Whitney U test, and propor-
tions were compared by use of the x2 test or Fisher’s exact test,
as appropriate. Univariate und multivariate logistic regression
analyses were performed to analyze the factors that influenced
the vaccine’s performance.
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Table 1. Characteristics of 304 immunosuppressed patients randomized to receive a
subunit or virosomal influenza vaccine.
Patient characteristic
Subunit
vaccine group
( )np 151
Virosomal
vaccine group
( )np 153 P
Age, years 50.6  14.3 50.4  14.3 .7
Male sex 103/151 (68.2) 106/153 (69.3) .9
Creatinine clearance, mL/mina 97.7  37.1 91.1  36.4 .1
Current smoker 42/151 (27.8) 40/153 (26.1) .6
Charlson comorbidity index,b mean score (range) 1 (0–5) 1 (0–5) .7
Subcutaneous administration of vaccine 44/140 (31.4) 38/138 (27.5) .4
Duration of time from vaccination to follow-up, days 53.5  48.3 50.0  45.0 .5
Never vaccinated against influenza 20/151 (13.2) 26/153 (17.0) .4
Patients with rheumatologic disease
All 28/151 (18.5) 19/153 (12.4) .8
Chronic idiopathic arthritis 18/28 (64.3) 10/19 (52.6)
Spondylarthritis 7/28 (25.0) 6/19 (31.6)
Autoimmune connectivitis 1/28 (3.6) 2/19 (10.5)
Sarcoidosis 1/28 (3.6) 1/19 (5.3)
Vasculitis 1/28 (3.6) 0/19 (0.0)
Patients with rheumatologic disease who received treatment
With 1 immunosuppressive drug 9/28 (32.1) 4/19 (21.1) .7
With 2 immunosuppressive drugs 11/28 (39.3) 10/19 (52.6)
With 3 immunosuppressive drugs 8/28 (28.6) 5/19 (26.3)
Patients with rheumatologic disease who were never vaccinated 15/28 (53.6) 8/19 (42.1) .5
Patients with nephrologic disease
All 60/151 (39.7) 66/153 (43.1) .8
Long-term dialysis 21/60 (35.0) 26/66 (39.4)
Renal transplant recipient 37/60 (61.6) 37/66 (56.1)
Other 2/60 (3.3) 3/66 (4.5)
Patients with nephrologic disease who received treatment
Without immunosuppressive drugs 23/60 (38.3) 24/66 (36.4) .9
With 1 immunosuppressive drug 1/60 (1.7) 2/66 (3.0)
With 2 immunosuppressive drugs 13/60 (21.7) 15/66 (22.7)
With 3 immunosuppressive drugs 23/60 (38.3) 25/66 (37.9)
Patients with nephrologic disease who underwent transplantation
Time since transplant, years 8.4  6.5 6.8  5.9 .2
Time since start of dialysis, years 5.2  4.7 5.0  6.2 .8
Patients with nephrologic disease who were never vaccinated 1/60 (1.7) 9/66 (13.6) .01
HIV-infected patients
All 63/151 (41.7) 68/153 (44.4)
Risk groupsc
Men who have sex with men 27/63 (42.9) 28/68 (41.2) .3
Heterosexuals 30/63 (47.6) 26/68 (38.2)
Intravenous drug users 5/63 (7.9) 9/68 (13.2)
Stage of HIV infectiond
A 32/63 (50.8) 31/68 (45.6) .5
B 21/63 (33.3) 25/68 (36.8)
C 10/63 (15.9) 12/68 (17.6)
HIV-infected patients with HIV RNA !50 copies/mL 43/63 (68.3) 43/68 (63.2) .3
CD4 cell count of HIV-infected patients, cells/mL 463  238.9 461  236.3 .9
CD4 cell percentage of HIV-infected patients 23  9.3 25  8.2 .2
HIV-infected patients who received HAARTe 48/63 (76.2) 53/68 (77.9) .8
HIV-infected patients who were never vaccinated 4/63 (6.3) 9/68 (13.2) .1
NOTE. Data are proportion (%) of patients or mean values  standard deviation, unless otherwise
indicated. HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus.
a Values for patients who underwent dialysis are excluded.
b Charlson et al. [15].
c Risk factors were unknown for 1 patient in the subunit vaccine group and for 5 patients in the
virosomal vaccine group.
d Acccording to definition of the Centers for Disease Control and Prevention [16].
e HAART with at least 3 active drugs.
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Table 2. Immunogenicity of a subunit influenza vaccine and a virosomal influenza vaccine in immunosuppressed
patients.
Vaccine characteristic
Subunit
vaccine group
( )np 151
Virosomal
vaccine group
( )np 153 P
Geometric mean anti-HA antibody titers (95% CI)
A1 California strain
Baseline 25.4 (21.0–30.7) 26.2 (21.8–31.5) .5
Follow-up 100.0 (80.4–125.7) 107.5 (86.8–133.1) .8
A1 Caledonia strain
Baseline 29.8 (23.0–36.1) 30.9 (25.1–38.1) .9
Follow-up 69.5 (55.4–87.2) 64.0 (52.3–78.3) .9
B Shanghai strain
Baseline 25.6 (20.6–31.8) 21.9 (18.1–26.3) .3
Follow-up 52.7 (42.2–65.7) 36.8 (30.6–44.4) .1
Seroconversiona rate
A1 California strain 94/151 (62.3) 90/153 (58.8) .4
A1 Caledonia strain 63/151 (41.7) 61/153 (40.0) .1
B Shanghai strain 41/151 (27.2) 31/153 (20.3) .4
Protective anti-HI antibody titers of 40
A1 California strain
Baseline 43/151 (28.5) 39/153 (25.5) .5
Follow-up 109/151 (72.2) 116/153 (75.8) .4
A1 Caledonia strain
Baseline 41/151 (27.2) 41/153 (26.8) .9
Follow-up 99/151 (65.6) 97/153 (63.4) .6
B Shanghai strain
Baseline 31/151 (20.5) 21/153 (13.7) .6
Follow-up 74/151 (49.0) 59/153 (38.6) .06
Seroprotection rate for patients with nonprotective baseline titers
A1 California strain 66/108 (61.1) 77/114 (67.5) .3
A1 Caledonia strain 58/110 (52.7) 56/112 (50.0) .6
B Shanghai strain 43/120 (35.8) 40/132 (30.3) .3
Protective anti-HA antibody titers after vaccination
In all immunosuppressed patients
2 strains 89/151 (59.0) 107/153 (70.0) .038
3 strains 63/151 (41.7) 46/153 (30.1)
In renal transplant recipients
2 strains 27/37 (73.0) 28/37 (75.7) .7
3 strains 10/37 (27.0) 9/37 (24.3)
In patients who received long-term dialysis
2 strains 10/21 (47.6) 18/26 (69.2) .1
3 strains 11/21 (52.4) 8/26 (30.8)
In patients with rheumatologic disease
2 strains 18/28 (64.3) 16/19 (84.2) .1
3 strains 10/28 (35.7) 3/19 (15.8)
In patients with HIV infection
2 strains 32/63 (50.8) 43/68 (63.2) .1
3 strains 31/63 (49.2) 25/68 (36.8)
Seroconversiona rate
In all immunosuppressed patients
2 strains 118/151 (78.1) 128/153 (83.7) .18
3 strains 34/151 (22.5) 25/153 (16.3)
For renal transplant recipients
2 strains 30/37 (81.1) 33/37 (89.2) .5
3 strains 7/37 (18.9) 4/37 (10.8)
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Table 2. (Continued.)
Vaccine characteristic
Subunit
vaccine group
( )np 151
Virosomal
vaccine group
( )np 153 P
In patients who received long-term dialysis
2 strains 17/21 (81.0) 19/26 (73.1) .7
3 strains 4/21 (19.0) 7/26 (26.9)
In patients with rheumatologic disease
2 strains 20/28 (71.4) 18/19 (94.7) .06
3 strains 8/28 (28.6) 1/19 (5.3)
In patients with HIV infection
2 strains 49/63 (77.8) 55/68 (80.9) .6
3 strains 14/63 (22.2) 13/68 (19.1)
NOTE. Data are proportion (%) of immunosuppressed patients, unless otherwise indicated. CI, confidence interval; HA, hemagglutinin;
HI, hemagglutination inhibition; HIV, human immunodeficiency virus.
a Seroconversion is defined as an increase in anti-HA antibody titers of 4 in comparison to baseline.
RESULTS
Study subjects. A total of 304 subjects were enrolled: 151 were
randomized to receive the subunit vaccine, and 153 were ad-
ministered the virosomal vaccine. Patients’ characteristics are
presented in table 1.
Most of the patients with rheumatologic disease received
tumor necrosis factor (TNF)–a blockers (i.e., 21 [75%] of 28
patients who received the subunit vaccine and 13 [68%] of 19
patients who received the virosomal vaccine), mostly in com-
bination with prednisone or methotrexate. Almost one-half of
patients with rheumatologic disease had never received an in-
fluenza vaccine before.
The immunosuppressive regimens of renal transplant recip-
ients were based on prednisone and calcineurine inhibitors,
either alone or in combination with azathioprine or myco-
phenolate. The percentage of patients who had never been vac-
cinated against influenza was higher in the virosomal vaccine
group than in the subunit vaccine group (9 [13.6%] of 66
patients vs. 1 [1.7%] of 60 patients; ).Pp .015
The HIV-infected patients in the 2 vaccine groups were at
similar stages of HIV infection, according to the definition of
the Centers for Disease Control and Prevention (table 1). At
least two-thirds of the patients were receiving highly active
antiretroviral therapy (HAART) including at least 3 antiret-
roviral drugs. Accordingly, approximately two-thirds of the pa-
tients had HIV viremia below the threshold of detection (!50
HIV RNA copies/mL). Of the 304 patients, 267 (88%) had their
follow-up serum samples obtained before the end of the local
influenza epidemic during the 2005–2006 influenza season (i.e.,
before the middle of March 2006) [17].
Immunogenicity. The mean duration between obtaining
baseline serum samples and obtaining follow-up serum samples
was comparable for the 2 vaccine groups (∼50 days) (table 1).
Baseline geometric mean anti-HA antibody titers were similar
for all 3 vaccine strains and increased significantly ( )P ! .001
after vaccination for all 3 vaccine strains (table 2). Postvac-
cination anti-HA antibody titers were highest for the A1 Cal-
ifornia strain (followed by the A1 Caledonia strain) and lowest
for the B Shanghai strain.
At baseline, protective anti–hemagglutination inhibition (HI)
antibody titers against the A1 California strain and the A1
Caledonia strain were observed in approximately one-fourth
of patients from both vaccine groups, but protective anti-HI
antibody titers against the B Shanghai strain were observed in
a fewer number of patients from both vaccine groups (table
2). After vaccination, the number of patients from both vaccine
groups with protective anti-HI titers against all 3 strains in-
creased significantly ( ): 109 (72%) of 151 patients fromP ! .001
the subunit vaccine group and 116 (76%) of 153 patients from
the virosomal vaccine group had a protective anti-HA antibody
titer against the A1 California strain; 99 (66%) of 151 patients
from the subunit vaccine group and 97 (63%) of 153 patients
from the virosomal vaccine group had a protective anti-HA
antibody titer against the A1 Caledonia strain; and 74 (49%)
of 151 patients from the subunit vaccine group and 59 (39%)
of 153 patients from the virosomal vaccine group had a pro-
tective anti-HA antibody titer against the B Shanghai strain.
The 2 vaccines did not differ in terms of vaccine response
against the A1 California strain and the A1 Caledonia strain.
There was a trend toward a better vaccine response against the
B Shanghai strain among patients who received the subunit
vaccine, compared with patients who received the virosomal
vaccine (74 [49%] of 151 patients vs. 59 [39%] of 153 patients;
). However, baseline rates of protective anti-HA titersPp .06
were lower in the virosomal vaccine group than in the subunit
vaccine group (21 [14%] of 153 patients vs. 31 [21%] of 151
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Table 3. Adverse effects of a subunit influenza vaccine and a virosomal influenza vaccine in
immunosuppressed patients.
Adverse effect in patient
Subunit
vaccine group
( )np 151
Virosomal
vaccine group
( )np 153 P
Immediate reactions
Any 14/151 (9.3) 15/153 (9.8) .8
Local pain 6/14 (42.9) 9/15 (60.0) .5
Local redness 1/14 (7.1) 1/15 (6.7)
Vasovagale syncope 2/14 (14.3) 0/15 (0.0)
Anaphylaxia 0/14 (0.0) 0/15 (0.0)
Local symptoms during the first 7 days after vaccination
Pain 38/129 (29.5) 55/139 (39.6) .3
Duration of pain, days 0.8  1.4 1.2  1.6 .2
Redness 17/125 (13.6) 13/136 (9.6) .2
Diameter of redness, cm 0.7  1.0 1.1  1.4 .2
Warmth 7/122 (5.7) 11/132 (8.3) .4
Swelling 14/125 (11.2) 13/133 (9.8) .7
Diameter of swelling, cm 1.8  1.1 2.6  1.1 .1
Duration of swelling, days 0.7  1.5 0.9  1.7 .7
Systemic reactions during the first 7 days after vaccination
Shivering 12/124 (9.7) 6/133 (4.5) .1
Temperature 37.8C 4/125 (3.2) 4/125 (3.2) .9
Fatigue 30/126 (23.8) 36/136 (26.5) .5
Malaise 19/123 (15.4) 13/129 (10.1) .2
Headache 27/124 (21.8) 27/133 (20.3) .7
Muscle pain 16/124 (12.9) 17/133 (12.8) .9
Arthralgia 14/123 (11.4) 17/133 (12.8) .7
Duration of arthralgia, days 1.3  1.7 1.3  1.6 .7
Consultation with a physician 3/125 (2.4) 0/136 (0.0) .1
Consumption of additional drugs 9/125 (7.2) 8/137 (5.8) .4
Not willing to receive influenza vaccine next year 1/119 (0.8) 7/129 (5.4) .04
NOTE. Data are proportion (%) of patients or mean values  standard deviation.
patients). The seroprotection rates between the 2 vaccine groups
did not differ among patients with nonprotective baseline titers
against the 3 individual vaccine strains.
The percentage of patients with protection against all 3 vac-
cine strains was significantly higher after vaccination for the
subunit vaccine group than for the virosomal vaccine group
(62 [41%] of 151 patients vs. 46 [30%] of 153 patients; Pp
). A similar trend was seen for subgroups of patients with.03
HIV infection, with rheumatologic disease, or who received
long-term dialysis, but the trend did not reach statistical
significance.
Reactogenicity. Overall, the subunit and virosomal vac-
cines were comparable with regard to the frequency of adverse
effects (table 3). Pain was by far the most frequent local re-
action, with 38 (30%) of 129 patients in the subunit vaccine
group and 55 (40%) of 139 patients in the virosomal vaccine
group having reported pain at the site of injection.
Fatigue was the most frequently reported systemic reaction,
occurring in approximately one-fourth of patients. The disease-
specific scores for the patients in both vaccine groups with
rheumatologic disease were comparable; scores either decreased
4 weeks after vaccination or remained stable (table 4).
Factors influencing vaccine response. For the analysis of
the factors influencing vaccine response, patients from both
vaccine groups were pooled. Vaccine response was defined as
a protective anti-HA antibody titer against all 3 vaccine strains
in the postvaccination (i.e., follow-up) serum sample. Among
renal transplant recipients, vaccine response was not statistically
significantly associated (by use of univariate analysis) with age,
history of past opportunistic infections, leukocyte or lympho-
cyte count at baseline or during the 3 months preceding vac-
cination, subcutaneous administration of the vaccine, immu-
nosuppressive treatment, or the time since transplantation
(table 5). However, in the multivariate analysis, which included
time since transplantation, treatment with mycophenolate or
purinantagonists, and number of immunosuppressive drugs,
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Table 4. Disease activity in patients with chronic rheumatologic disease at baseline and after
vaccination with a subunit or virosomal vaccine.
Patients, disease-specific score
Subunit
vaccine
Virosomal
vaccine P
DAS of 24 patients with rheumatoid arthritis, mean  SD
Baseline 3.6  1.3 3.0  1.3 .3
Follow-up 3.2  1.2 2.1  1.2 .05
BASDAI of 13 patients with ankylosing spondylitis, mean  SD
Baseline 2.9  1.7 3.3  1.1 .08
Follow-up 2.0  1.1 2.4  1.4 .4
ECLAM of 3 patients with lupus erythematodes, mean
Baseline 1.5 1 .1
Follow-up 1.5 1 .1
DEI of 2 patients with Wegener granulomatosis, mean
Baseline 4 4 1.99
Follow-up 2 4 .3
NOTE. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS, Disease Activity Score; DEI, Disease
Extend Index; ECLAM, European Consensus Lupus Activity Measurement; SD, standard deviation.
Table 5. Factors influencing immune response to influenza vaccination in 73 renal transplant
recipients.
Factor
Protective anti-HA
antibody titers against
P
2 strains
( )np 54
3 strains
( )np 19
Age, years 55.6  10.2 52.0  13.6 .4
History of opportunistic infections 21 (38.9) 4 (21.1) .2
Lymphocyte count at time of vaccination, g/L 1.0  0.57 1.7  0.3 .08
Nadir of lymphocyte count 3 months before vaccination, g/L 0.8  0.7 1.1  0.7 .3
Leukocyte count at time of vaccination, g/L 8.4  2.7 7.8  2.0 .3
Nadir of leukocyte count 3 months before vaccination, g/L 7.0  2.1 6.1  1.5 .1
Subcutaneous administration of vaccine 44 (81.5) 18 (94.7) .2
Patients who received immunosuppressive drug treatment
at time of vaccination
With prednisone 50 (92.6) 19 (100) .3
With sirolimus 6 (11.1) 3 (15.8) .6
With calcineurin inhibitors 46 (85.2) 16 (84.2) .99
With azathioprine 14 (25.9) 7 (36.8) .3
With mycophenolate 27 (50.0) 5 (26.3) .1
Patients who received treatment
With 1 immunosuppressive drug 1 (1.8) 0 (0.0) .3
With 2 immunosuppressive drugs 18 (33.3) 8 (42.1)
With 3 immunosuppressive drug 36 (66.6) 11 (57.9)
Time since transplantation, years 7.5  6.5 7.6  5.6 .9
NOTE. Data are no. (%) of patients or mean values  standard deviation. HA, hemagglutinin.
treatment with mycophenolate was the only statistically sig-
nificant risk factor associated with nonresponse to vaccination
(odds ratio [OR], 0.2; 95% confidence interval [CI], 0.04–0.93;
).Pp .04
For HIV-infected patients, a CD4 cell count of 1200 cells/
mL or a CD4 cell percentage of 114%, the time since a CD4
cell percentage of 114%, receipt of HAART, and undetectable
HIV RNA in plasma at time of vaccination were statistically
significantly associated with a protective vaccine response in
the univariate analysis (table 6). In the multivariate analysis,
only an undetectable HIV plasma RNA level !50 copies/mL
was a statistically significant predictor of vaccine response (OR,
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Table 6. Factors influencing vaccine response in 131 patients infected with human immunodeficiency
virus (HIV).
Factor
Protective anti-HA antibody titers
against
P2 strains 3 strains
Absolute CD4 cell count, cells/mL 437.5  234.8 495.9  237.1 .1
Nadir of absolute CD4 cell count, cells/mL 234.9  199.4 202.6  151.9 .3
Time since nadir of absolute CD4 cell count, days 1789  4491 1580  1279 .7
Patients with CD4 cell counts .02
200 cells/mL 62/74 (83.8) 55/57 (96.5)
!200 cells/mL 12/74 (16.2) 2/57 (3.5)
Time since CD4 cell count 200 cells/mL, years 2.2  3.7 5.4  3.7 .1
Relative CD4 cell count,% 23.5  9.3 26.0  7.9 .1
CD4/CD8 cell count ratio, median (range) 0.46 (0.1–2.0) 0.5 (01–2.1) .1
Patients with CD4 cell percentage of 114% 64/74 (86.5) 54/57 (94.7) .04
Time since CD4 cells 114%, median years (range) 3.7 (0.1–14.7) 3.9 (0.1–15.6) .8
Patients who received HAART 53/74 (71.6) 48/57 (84.2) .04
Plasma log10 HIV RNA at time of vaccination, median (range) 3.5 (0–11.2) 1.6 (0–11.8) .006
NOTE. Data are proportion (%) of patients or mean values  standard deviation, unless otherwise indicated. HA, hemag-
glutinin; HAART, highly active antiretroviral therapy.
3.7; 95% CI, 1.63–8.46; ). For patients who receivedPp .002
long-term hemodialysis, only advanced age was predictive of
achieving protective titers against all 3 vaccine strains (median,
58 vs. 71 years; OR, 1.05; 95% CI, 1.0–1.1; ). For pa-Pp .03
tients with rheumatologic disease, neither the characteristics of
the disease nor the patients’ treatments were predictive of re-
sponse against all 3 vaccine strains (table 7).
DISCUSSION
Our study compared the immunogenicity and reactogenicity
of a virosomal influenza vaccine with the immunogenicity and
reactogenicity of a subunit influenza vaccine in adult patients
with immunosuppression due to long-term dialysis, renal trans-
plantation, rheumatic disease, or HIV infection. To our knowl-
edge, such an analysis has not been performed before.
The subunit vaccine was slightly more immunogenic than
the virosomal vaccine in terms of the percentage of patients
who reached a protective anti-HA antibody titer against all 3
vaccine strains (41% vs. 30%). This trend was also observed
for subgroups of patients with HIV infection, with rheuma-
tologic disease, or who received long-term dialysis but not for
renal transplant recipients.
The overall response rate to all 3 vaccine strains was low
(i.e., !50% of patients had protective anti-HA antibody titers
against all 3 vaccine strains after vaccination). Among sub-
groups of patients, however, patients with HIV infection and
patients who received dialysis showed higher response rates
(∼50% of patients) than renal transplant recipients and patients
with rheumatologic disease (∼25% of patients). This difference
is probably attributable to the degree of immunosuppression
in the different subgroups of patients; most patients with HIV
infection received efficacious antiretroviral therapy (i.e.,
HAART), and most patients who received dialysis received no
additional immunosuppressive treatment.
The vaccine response rate observed among patients who re-
ceived long-term dialysis was comparable to earlier findings [1,
4, 18] that showed a lower vaccine response rate, compared
with healthy subjects [1, 4]. In our study, patients who received
dialysis had a lower response rate than the patients studied by
Song et al. [19], who also showed that the vaccine response
rate seems to decrease the longer the duration of dialysis. Our
patients received dialysis for an average of 5 years before the
start of our study, which is considerably longer than the du-
ration of dialysis among the patients in the study by Song et
al. [19] and may explain the lower response rates in our study.
A comparison of vaccine immunogenicity in HIV-infected
patients observed in our study with that found in the literature
is hampered by differences between the study populations. Most
of the earlier studies were conducted before the introduction
of HAART, and the stratification of patient groups according
to surrogates of immunosuppression (such as CD4 cell count)
varies between studies [3, 8, 20–22]. However, among adult
patients with HIV infection, the vaccine response rate is gen-
erally higher among patients who received antiretroviral treat-
ment [3]. Most studies emphasized the importance of a high
CD4 cell count to a higher vaccine response rate [8, 21]. These
studies were performed before or at the beginning of the
HAART era, when therapy had no long-term suppressive effect
on the HIV RNA level in a patient. In our study, only the
HAART-associated undetectable plasma HIV RNA level, not
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Table 7. Factors influencing immune response to influenza vaccination in 47 patients with rheumatologic disease.
Factor
Protection against
2 strains
( )np 34
Protection against
all 3 strains
( )np 13 P
Age, years 51.2  12.5 48.4  14.5 .5
Male sex 20 (58.8) 7 (53.8) .7
Type of heumatologic disease
Autoimmune connectivitis 2 (5.9) 1 (7.7) .4
Chronic idiopathic polyarthritis 21 (61.8) 7 (53.8)
Sarcoidosis 0 (0.0) 1 (7.7)
Spondarthritis 10 (29.4) 3 (23.1)
Vasculitis 1 (2.9) 1 (7.7)
Duration of rheumatologic disease, years 10.3  7.8 9.6  8.2 .7
Lymphocyte count at time of vaccination, g/L 1.9  0.8 1.6  0.7 .2
Nadir of lymphocyte count 3 months before vaccination, median (range), g/L 1.3 (0.4–7.7) 1.3 (0.2–2.7) .7
Leukocyte count at time of vaccination, g/L 7.7  2.1 6.7  1.8 .1
Smoker 7 (20.6) 2 (15.4) .99
Elevated transaminase levels 1 (2.9) 1 (7.7) .4
Liver cirrhosis 1 (2.9) 1 (7.7) .4
Charlson comorbidity index, median score (range) 1 (1–3) 1 (1–3) .2
Diabetes 2 (5.9) 1 (7.7) .99
First influenza vaccination ever 17 (50.0) 6 (46.2) .5
Received subcutaneous vaccination 2 (5.9) 1 (7.7) .99
No. of immunosuppressive drugs received 1.9  0.8 1.9  0.7 .8
Received TNF-a blockers 25 (73.5) 9 (69.2) .99
Received methotrexate 20 (58.8) 7 (53.8) .7
Duration of treatment, years 8.3  8.4 9.2  9.3 .7
Type of drug used for treatment
Prednisone 14 (41.2) 3 (23.1) .2
Purinantagonists 3 (8.8) 1 (7.7) .99
Azathioprin 1 (2.9) 1 (7.7) .4
Calcineurinantagonist 2 (5.9) 2 (15.4) .3
NOTE. Data are no. (%) of patients or mean values  standard deviation, unless otherwise indicated. TNF, tumor necrosis factor.
the CD4 cell count, was an independent predictor of a higher
vaccine response rate. This finding is in accordance with that
of Yamanaka et al. [23], who showed an association between
cellular response against the H1N1 influenza antigen and HIV
RNA level but not CD4 cell count. Therefore, suppression of
HIV replication may be more important than the CD4 cell
count for predicting immune response against influenza vac-
cine, and recommendations against influenza vaccination for
patients with CD4 cell counts of !100 cells/mL should be ques-
tioned. We argue that patients who are responding to HAART
(on the basis of viral load) should be considered for influenza
vaccination pending further studies.
Both our study and the studies of others demonstrated low
vaccine response rates among renal transplant recipients [4, 24,
25]. The immunosuppressive treatment regimen seems to play
an important role. Significant increases in anti-HA antibody
titers were seen in patients who received prednisone, cyclo-
sporine, and azathioprine [4, 25]. However, treatment with
mycophenolate mofetil was associated with a lower vaccine
response rate in our study and the studies of others [25, 26].
As a group, patients with rheumatic disease who underwent
immunosuppressive treatment had a low vaccine response rate
(19% of these patients were protected against all 3 vaccine
strains). However, two-thirds of our patients received at least
2 immunosuppressive drugs, and one-half of them were treated
with TNF-a inhibitors, which may explain the poor vaccine
response. Our study population was too small for an analysis
of individual risk factors. However, a poor vaccine response
associated with treatment with TNF-a inhibitors alone or in
combination with methotrexate was found in a study of patients
with rheumatoid arthritis who had been treated for a median
of 0.7–1 year before vaccination [2]. Also, treatment with aza-
thioprine has been associated with low seroconversion rates,
compared with treatment with hydroxychloroquine and pred-
nisone, among patients with systemic lupus erythematodes
[27].
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For both vaccines, the rate of immunogenicity was found to
be different for each of the 3 vaccine strains. The vaccine re-
sponse rate was highest against the A1 California vaccine strain
and lowest against the B Shangai strain. A lower rate of im-
munogenicity for B type strains has been found in some but
not all studies that used the same or different vaccine strains
for immunosuppressed patients [24, 25, 28]. The immune re-
sponse to different vaccine strains seems to be more balanced
in immunocompetent populations [1, 3, 4, 8, 22, 25]. Sub-
cutaneous vaccination did not affect vaccine response in our
study, as has been shown for subcutaneous vaccination against
hepatitis B [29].
Split and virosomal vaccines were equally well tolerated by
patients in our study. Furthermore, there were no signs or
symptoms for the activation of the underlying disease in HIV-
infected patients and patients with rheumatologic disease dur-
ing postvaccination surveillance. This finding is in accordance
with the findings of other studies, in which influenza vaccines
were found to be safe for immunosuppressed patients [8, 27,
28, 30]. We did not evaluate postvaccination dynamics in HIV
viral load. Two other studies did not find an increase in viral
load after vaccination, although they chose a relatively high
(400 copies/mL) cutoff level [8, 21]. Gu¨nthard et al. [31] dem-
onstrated a slight but transient increase in HIV RNA levels in
patients with HIV RNA levels of !50 copies/mL during the
first 2 weeks after vaccination.
In conclusion, a subunit influenza vaccine was found to be
slightly more immunogenic than a virosomal vaccine in im-
munosuppressed patients with various underlying diseases. Vac-
cine response was mostly influenced by the degree of immu-
nosuppression, with higher immunogenicity in patients who
received long-term dialysis and HIV-infected patients receiving
efficacious antiretroviral treatment than in renal transplant re-
cipients and patients receiving immunosuppressive treatment
for chronic rheumatologic diseases. The viral load in plasma
rather than the CD4 cell count predicted the immunogenicity
of the influenza vaccine in HIV-infected patients. We argue that
HIV-infected patients who receive efficacious antiretroviral
treatment should be offered influenza vaccination regardless of
their CD4 cell count.
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